Swedbank AB Decreases Stock Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Swedbank AB reduced its stake in Edwards Lifesciences by 27.6%, selling over 215,000 shares and owning about 0.10% of the company valued at approximately $40.98 million.
• Analysts have raised their price targets for Edwards Lifesciences, with Evercore ISI increasing it from $77.00 to $80.00 and Piper Sandler raising it to $90.00, reflecting overall positive sentiment among analysts.
• Edwards Lifesciences reported earnings of $0.67 per share, beating estimates and showing a revenue increase of 11.9% year-over-year, with projected guidance for earnings between 0.540-0.600 EPS for Q3 2025.

Swedbank AB lowered its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 27.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 565,410 shares of the medical research company's stock after selling 215,076 shares during the quarter. Swedbank AB owned about 0.10% of Edwards Lifesciences worth $40,981,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the company. Quantbot Technologies LP acquired a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $26,000. Vega Investment Solutions bought a new position in Edwards Lifesciences in the 4th quarter valued at about $27,000. SouthState Corp purchased a new stake in Edwards Lifesciences in the 1st quarter valued at about $27,000. Global X Japan Co. Ltd. increased its stake in Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after buying an additional 216 shares during the last quarter. Finally, Tradewinds Capital Management LLC increased its stake in Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after buying an additional 205 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In related news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on EW shares. Truist Financial increased their price objective on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a research note on Friday, July 25th. Canaccord Genuity Group raised their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a research note on Friday, July 25th. Barclays raised their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday, July 25th. Daiwa America upgraded shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 29th. Finally, Wall Street Zen lowered shares of Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 13th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $87.17.

Edwards Lifesciences Trading Down 1.5%

NYSE:EW traded down $1.16 during trading hours on Thursday, reaching $74.04. The company's stock had a trading volume of 2,960,694 shares, compared to its average volume of 4,440,119. The firm has a market capitalization of $43.47 billion, a price-to-earnings ratio of 10.66, a PEG ratio of 3.62 and a beta of 1.07. The firm has a 50-day simple moving average of $78.84 and a 200-day simple moving average of $75.47. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm's revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.